GP IIb/IIIa inhibitors during primary percutaneous coronary intervention for STEMI: new trial and registry data.
- 1 September 2008
- journal article
- research article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 10 (5) , 424-430
- https://doi.org/10.1007/s11886-008-0066-5
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- The Safety and Efficacy of Glycoprotein IIb/IIIa Inhibitors for Primary Angioplasty: More Options to Choose and More Time to DecideJournal of the American College of Cardiology, 2008
- The Relative Safety and Efficacy of Abciximab and Eptifibatide in Patients Undergoing Primary Percutaneous Coronary InterventionJournal of the American College of Cardiology, 2008
- Eptifibatide vs Abciximab as Adjunctive Therapy During Primary Percutaneous Coronary Intervention for Acute Myocardial InfarctionMayo Clinic Proceedings, 2007
- Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-upEuropean Heart Journal, 2007
- ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary ArticleCirculation, 2006
- The use of GP IIb/IIIa inhibitors into new perspectives: pre-catheterization laboratory administrationEuropean Heart Journal Supplements, 2005
- Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular functionThe American Journal of Cardiology, 2004
- Abciximab-Supported Infarct Artery Stent Implantation for Acute Myocardial Infarction and Long-Term SurvivalCirculation, 2004
- Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial InfarctionNew England Journal of Medicine, 2002
- Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial InfarctionNew England Journal of Medicine, 2001